EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast

Journal of Clinical Oncology

Volumn 24, Issue 2, 2006, Pages 268-273

  Bachmann, Ingeborg M ^a   Halvorsen, Ole J ^a   Collett, Karin ^a   Stefansson, Ingunn M ^a   Straume, Oddbjørn ^a   Haukaas, Svein A ^a   Salvesen, Helga B ^a   Otte, Arie P ^a   Akslen, Lars A ^a  

^a UNIVERSITY OF BERGEN   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER; DNA BINDING PROTEIN; EZH2 PROTEIN, HUMAN; KI 67 ANTIGEN; TRANSCRIPTION FACTOR;

ARTICLE; BREAST CANCER; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL FEATURE; CONTROLLED STUDY; ENDOMETRIUM CANCER; EZH2 GENE; FEMALE; GENE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MELANOMA; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; TUMOR CELL; BREAST TUMOR; CHEMISTRY; ENDOMETRIUM TUMOR; IMMUNOHISTOCHEMISTRY; MORTALITY; PATHOLOGY; PROSTATE TUMOR; SKIN TUMOR;

BREAST NEOPLASMS; CELL PROLIFERATION; DNA-BINDING PROTEINS; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MELANOMA; PROSTATIC NEOPLASMS; SKIN NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 33644822360     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.01.5180     Document Type: Article

References (22)

1. Simon JA, Tamkun JW: Programming off and on states in chromatin: Mechanisms of polycomb and trithorax group complexes. Curr Opin Genet Dev 12:210-218, 2002
2. Bracken AP, Pasini D, Capra M, et al: EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. Embo J 22:5323-5335, 2003
3. Tang X, Milyavsky M, Shats I, et al: Activated p53 suppresses the histone methyltransferase EZH2 gene. Oncogene 23:5759-5769, 2004
4. Varambally S, Dhanasekaran SM, Zhou M, et al: The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419:624-629, 2002
5. Kleer CG, Cao Q, Varambally S, et al: EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci U S A 100:11606-11611, 2003
6. Raaphorst FM, Meijer CJ, Fieret E, et al: Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia 5:481-488, 2003
7. Kirmizis A, Bartley SM, Farnham PJ: Identification of the polycomb group protein SU(Z)12 as a potential molecular target for human cancer therapy. Mol Cancer Ther 2:113-121, 2003
8. Straume O, Sviland L, Akslen LA: Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma. Clin Cancer Res 6:1845-1853, 2000
9. Halvorsen OJ, Haukaas SA, Akslen LA: Combined loss of PTEN and p27 expression is associated with tumor cell proliferation by Ki-67 and increased risk of recurrent disease in localized prostate cancer. Clin Cancer Res 9:1474-1479, 2003
10. Stefansson IM, Salvesen HB, Akslen LA: Prognostic impact of alterations in P-cadherin expression and related cell adhesion markers in endometrial cancer. J Clin Oncol 22:1242-1252, 2004
11. Collett K, Stefansson IM, Eide J, et al: A Basal epithelial phenotype is more frequent in interval breast cancers compared with screen detected tumors. Cancer Epidemiol Biomarkers Prev 14:1108-1112, 2005
12. Elston CW, Ellis IO: Pathological prognostic factors in breast cancer, I: The value of histological grade in breast cancer - Experience from a large study with long-term follow-up. Histopathology 19:403-410, 1991
13. Kononen J, Bubendorf L, Kallioniemi A, et al: Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4:844-847, 1998
14. Hoos A, Urist MJ, Stojadinovic A, et al: Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol 158:1245-1251, 2001
15. Hamer KM, Sewalt RG, den Blaauwen JL, et al: A panel of monoclonal antibodies against human polycomb group proteins. Hybrid Hybridomics 21:245-252, 2002
16. Aas T, Borresen AL, Geisler S, et al: Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. Nat Med 2:811-814, 1996
17. Bachmann IM, Straume O, Akslen LA: Altered expression of cell cycle regulators Cyclin D1, p14, p16, CDK4 and Rb in nodular melanomas. Int J Oncol 25:1559-1565, 2004
18. Halvorsen OJ, Hostmark J, Haukaas S, et al: Prognostic significance of p16 and CDK4 proteins in localized prostate carcinoma. Cancer 88:416-424, 2000
19. Stefansson IM, Salvesen HB, Immervoll H, et al: Prognostic impact of histological grade and vascular invasion compared with tumour cell proliferation in endometrial carcinoma of endometrioid type. Histopathology 44:472-479, 2004
20. Salvesen HB, Das S, Akslen LA: Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis. Clin Cancer Res 6:153-159, 2000
21. Otte AP, Kwaks TH: Gene repression by polycomb group protein complexes: A distinct complex for every occasion? Curr Opin Genet Dev 13:448-454, 2003
22. Shapiro GI, Edwards CD, Kobzik L, et al: Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res 55:505-509, 1995